ICON
Runs outsourced clinical development programs for drug and medical-device makers worldwide.
Something off on this page? Send us feedback.
Profile
Provides outsourced drug- and device-development services across clinical research, functional services, real-world evidence, and consulting. A global operating network combines clinical execution with data and technology, while revenue depends on continued outsourcing, accurate long-duration contract estimates, and effective controls over revenue recognition.
Provides outsourced drug- and medical-device development services to pharmaceutical, biotechnology, medical-device, government, and public-health clients. Clinical research services sit at the core, complemented by functional services, early- and late-phase work, real-world evidence, market access, and scientific communications.
Built from Dublin into a global operating network, combining clinical operations with data and technology. The PRA Health Sciences acquisition materially expanded its workforce, geographic reach, and access to diverse patient populations.
Revenue depends on customers continuing to outsource complex development programs and on accurate cost-to-complete estimates for long-duration contracts. Following findings of improper revenue adjustments and contract-accounting errors, internal-control remediation covering oversight, procedures, training, and manual adjustments remains in progress.
Company facts
Key statistics
Year to date −9.9% · Average volume (30d) 723.4K
Analysts
Unavailable right now.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026Q2 FY26 | $2.55 | $2.56 | +0.4% | $2.00B | $2.06B | +3.0% | −7.10% |
| Jun 23, 2026Q1 FY26 | $2.43 | $1.37 | −43.6% | $2.00B | $2.03B | +1.8% | +10.86% |
| Jun 10, 2026Q1 FY26 | $2.47 | $2.52 | +2.0% | $1.99B | $2.11B | +6.1% | +3.69% |
| Jun 3, 2026Q1 FY26 | $3.20 | $2.52 | −21.3% | $1.99B | $2.11B | +6.1% | +6.18% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $2.00B | $2.02B | $2.04B | $2.11B | $2.03B | $2.06B | |
| Gross profit | $558.7M | $561.6M | $456.0M | $480.7M | $477.9M | $388.5M | |
| Operating income | $219.6M | $209.2M | $258.9M | $210.7M | $173.7M | $194.2M | |
| Net income | $154.2M | $183.0M | $2.4M | $149.2M | $104.8M | $72.6M | |
| Diluted EPS | $1.90 | $2.30 | $0.03 | $1.93 | $1.36 | $0.94 | |
| Gross margin | 27.9% | 27.8% | 22.3% | 22.8% | 23.5% | 18.8% | |
| Operating margin | 11.0% | 10.4% | 12.7% | 10.0% | 8.5% | 9.4% |
Fiscal years (4-quarter sums)FY21 $5.48B · FY22 $7.74B · FY23 $8.12B · FY24 $8.28B · FY25 $8.17B
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $928.4M · Total debt $3.49B · Total assets $16.40B · Shareholders' equity $9.38B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 76.57M · Float 75.85M · 99.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Artisan Partners Limited Partnership | 8.64M | 11.28% | 13F | Aug 13, 2026 |
| Wellington Management Group LLP | 5.32M | 6.95% | 13F | Aug 14, 2026 |
| FMR LLC | 5.27M | 6.88% | 13F | Aug 13, 2026 |
| Invesco Ltd. | 5.26M | 6.88% | 13F | Aug 14, 2026 |
| Harris Associates L P | 4.47M | 5.84% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 11, 2026 | Ronan Martin Murphy | director | −841 | $164.29 |
| Aug 11, 2026 | Ciaran Murray | director | −2,677 | $164.29 |
| Aug 11, 2026 | Julie O'Neill | director | −915 | $164.29 |
| Aug 11, 2026 | Anne Clem Whitaker | director | −841 | $164.29 |
| Aug 11, 2026 | Eugene Pacelli McCague | director | −841 | $164.29 |
Peers
- IQVIA
Scaled peer across clinical development, data, and commercialization
- Thermo Fisher Scientific
Integrated PPD rival in trials, FSP, and laboratory services
- Fortrea
Global CRO rival in full-service, FSP, and Phase I-IV delivery
- Medpace
Biotech-focused full-service CRO spanning Phase I-IV development
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ICON | $170.02 | +0.07% | $13.02B | 39.9 | 15.2 | 1.6 | +2.3% |
| IQVIA | $261.75 | +0.03% | $43.08B | 32.5 | 19.2 | 2.5 | +8.7% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Fortrea | $18.89 | +0.51% | $1.79B | — | 19.5 | 0.7 | −4.5% |
| Medpace | $600.65 | +0.03% | $16.77B | 35.2 | 32.7 | 6.0 | +17.2% |
| Median | 33.5 | 21.6 | 3.8 | +9.6% |